This previously unrecognized mechanism highlights the complexity of AR-mediated transcriptional repression in prostate cancer and suggests that targeting AR signaling may restore LTFe function, thereby enhancing ferroptosis sensitivity in CRPC. The gene discussed is AR; the disease is prostate cancer.